Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock*

Standard

Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock*. / Kreymann, K; de Heer, Geraldine; Nierhaus, Axel; Kluge, Stefan.

In: CRIT CARE MED, 2007.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{745c7d8bf5b349feadae0edf04c8d046,
title = "Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock*",
abstract = "OBJECTIVE:: There is ongoing debate about the efficacy of polyvalent immunoglobulins as adjunctive therapy for sepsis or septic shock. Two meta-analyses by the Cochrane collaboration calculated a significant reduction in mortality. However, data of the largest study were missing in one, and a subset of four high-quality studies failed to show an effect in the other. To broaden the database, we performed a meta-analysis of all randomized controlled studies published so far. DATA SOURCE:: MEDLINE, EMBASE, Cochrane Library of randomized trials, and personal files. STUDY SELECTION:: Meta-analysis of all published randomized controlled studies published on polyvalent immunoglobulins for treatment of sepsis or septic shock in adults, children, or neonates. DATA EXTRACTION:: Twenty-seven trials with a total of 2,202 patients fulfilled the inclusion criteria. DATA SYNTHESIS:: As the immunologic state of neonates is different than that of adults or older children, data were evaluated separately for each group. Fifteen trials on 1,492 adults could be included. The pooled effect on mortality was a relative risk of death (RR) of 0.79 (95% confidence interval [CI] 0.69-0.90, p",
author = "K Kreymann and {de Heer}, Geraldine and Axel Nierhaus and Stefan Kluge",
year = "2007",
language = "Deutsch",
journal = "CRIT CARE MED",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",

}

RIS

TY - JOUR

T1 - Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock*

AU - Kreymann, K

AU - de Heer, Geraldine

AU - Nierhaus, Axel

AU - Kluge, Stefan

PY - 2007

Y1 - 2007

N2 - OBJECTIVE:: There is ongoing debate about the efficacy of polyvalent immunoglobulins as adjunctive therapy for sepsis or septic shock. Two meta-analyses by the Cochrane collaboration calculated a significant reduction in mortality. However, data of the largest study were missing in one, and a subset of four high-quality studies failed to show an effect in the other. To broaden the database, we performed a meta-analysis of all randomized controlled studies published so far. DATA SOURCE:: MEDLINE, EMBASE, Cochrane Library of randomized trials, and personal files. STUDY SELECTION:: Meta-analysis of all published randomized controlled studies published on polyvalent immunoglobulins for treatment of sepsis or septic shock in adults, children, or neonates. DATA EXTRACTION:: Twenty-seven trials with a total of 2,202 patients fulfilled the inclusion criteria. DATA SYNTHESIS:: As the immunologic state of neonates is different than that of adults or older children, data were evaluated separately for each group. Fifteen trials on 1,492 adults could be included. The pooled effect on mortality was a relative risk of death (RR) of 0.79 (95% confidence interval [CI] 0.69-0.90, p

AB - OBJECTIVE:: There is ongoing debate about the efficacy of polyvalent immunoglobulins as adjunctive therapy for sepsis or septic shock. Two meta-analyses by the Cochrane collaboration calculated a significant reduction in mortality. However, data of the largest study were missing in one, and a subset of four high-quality studies failed to show an effect in the other. To broaden the database, we performed a meta-analysis of all randomized controlled studies published so far. DATA SOURCE:: MEDLINE, EMBASE, Cochrane Library of randomized trials, and personal files. STUDY SELECTION:: Meta-analysis of all published randomized controlled studies published on polyvalent immunoglobulins for treatment of sepsis or septic shock in adults, children, or neonates. DATA EXTRACTION:: Twenty-seven trials with a total of 2,202 patients fulfilled the inclusion criteria. DATA SYNTHESIS:: As the immunologic state of neonates is different than that of adults or older children, data were evaluated separately for each group. Fifteen trials on 1,492 adults could be included. The pooled effect on mortality was a relative risk of death (RR) of 0.79 (95% confidence interval [CI] 0.69-0.90, p

M3 - SCORING: Zeitschriftenaufsatz

JO - CRIT CARE MED

JF - CRIT CARE MED

SN - 0090-3493

ER -